Journal of Cancer Research and Clinical Oncology最新文献

{"title":"De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature.","authors":"Jin Sheng, Juan Jiao, Na Yan, Hongming Pan","doi":"10.1007/s00432-025-06132-x","DOIUrl":"10.1007/s00432-025-06132-x","url":null,"abstract":"<p><p>Primary MET amplification is an infrequent tumorigenic driver gene alteration identified in pulmonary neoplasms. Data on the effectiveness of MET-tyrosine kinase inhibitor (TKI) therapy in de novo MET amplification are relatively scarce, and there remains a dearth of empirical evidence supporting the use of precision therapy as first-line treatment for advanced non-small cell lung cancer (NSCLC) with primary MET amplification. We present a case of advanced lung adenocarcinoma in an elderly patient with primary MET amplification. The patient had an initial ECOG Performance Status (PS) 2. DNA-NGS analysis of tissue samples revealed a MET gene copy number (GCN) of 8, indicating MET amplification, without other oncogenic mutations associated with available drugs being detected. This finding was validated by MET fluorescence in situ hybridization (FISH), which showed cluster amplification. Initial treatment with savolitinib resulted in a sustained partial response lasting more than sixteen months. Our results suggest that savolitinib is effective and safe for the treatment of elderly patients with de novo amplified MET metastatic NSCLC and may therefore be considered a potential treatment option worthy of prospective study confirmation.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"82"},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brown adipose tissue activity on PET/CT and the course of Hodgkin lymphoma.","authors":"Taner Tan, Hülya Seymen, Sinem Civriz Bozdağ, Olga Meltem Akay, A Umur Topçu","doi":"10.1007/s00432-024-06076-8","DOIUrl":"10.1007/s00432-024-06076-8","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"85"},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Melanoma genomics- will we go beyond BRAF in clinics?","authors":"Justyna Mirek, Wiesław Bal, Magdalena Olbryt","doi":"10.1007/s00432-025-06112-1","DOIUrl":"10.1007/s00432-025-06112-1","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"81"},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Mechanistic insights into ¹²⁵I seed implantation therapy for Cholangiocarcinoma: focus on ROS-Mediated apoptosis and the role of GPX2.","authors":"Jun Luo, Zheng Yao, Weiren Liang, Danjun Song, Hui Zeng, Yi Jiang, Zhehan Bao, Jiaping Zheng, Yinan Ding","doi":"10.1007/s00432-025-06111-2","DOIUrl":"10.1007/s00432-025-06111-2","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"80"},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer.","authors":"Mengchao Wang, Shao Zhang, Dan Yi, Yan Ou, Shuqi Xie, Chuanxiu Zeng, Xueqian Qin, Lu Zhao, Zhen Wang, Fanming Kong, Liwei Chen","doi":"10.1007/s00432-025-06115-y","DOIUrl":"10.1007/s00432-025-06115-y","url":null,"abstract":"<p><p>The cellular-mesenchymal to epithelial transition factor (MET) gene plays a crucial role in maintaining cell homeostasis, motility, and apoptosis. In cancer, MET gene alterations promote tumour cell proliferation, invasion and metastasis. In non-small cell lung cancer (NSCLC), MET gene alterations include MET exon 14 (METex14) skipping mutation (METΔ14ex), MET amplification (METamp), MET fusion, and MET tyrosine kinase domain missense mutations (MET-TKD) and MET protein overexpression. Among them, the METΔ14ex is an independent driver gene of NSCLC. Three to four per cent of NSCLC patients carry METΔ14ex, and these patients have a poor prognosis and respond poorly to conventional chemotherapy. Small molecule highly selective MET inhibitors such as carmatinib, tepotinib, and cervotinib have shown promising efficacy and safety in clinical trials. Monoclonal antibodies, bispecific antibodies, antibody conjugate drugs, and immune checkpoint inhibitors provide more treatment space for patients with METΔ14ex. In this review, we summarize the current application and research of MET inhibitors and immune checkpoint inhibitors in NSCLC with METΔ14ex and provide recommendations for precise treatment of NSCLC patients with MET gene changes mutations. It also provides new ideas for solving the problems of synergistic effect and drug resistance in targeted therapy and immunotherapy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"78"},"PeriodicalIF":2.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the stromal molecular landscape: the correlation between p16 and α-SMA in epithelial ovarian cancer.","authors":"Marta Caretto, Angiolo Gadducci, Sabina Pistolesi, Diletta Mattiussi Tome, Giuseppe Nicolò Fanelli, Antonio Giuseppe Naccarato, Tommaso Simoncini","doi":"10.1007/s00432-025-06120-1","DOIUrl":"10.1007/s00432-025-06120-1","url":null,"abstract":"<p><strong>Introduction: </strong>The tumor microenvironment (TME) plays an essential role in promoting cancer initiation, progression and metastasis. Cancer-associated fibroblasts (CAFs) are a major constituent of the TME, but universal CAFs' markers have not yet been identified. We selected several new biomarkers [p16 and α-smooth muscle actin (α-SMA)] to investigate the molecular landscape in epithelial ovarian cancer (EOC), given to the unique TME of this malignancy.</p><p><strong>Methods: </strong>In total, 64 patients with a diagnosis of EOC who underwent primary debulking surgery (PDS) at the Department of Gynecology and Obstetrics of the University of Pisa were enrolled between January 2019 and June 2021. The stromal expression of α-SMA and p16 was investigated by using immunohistochemistry, and the correlations between p16 and α-SMA immunoreactivity and BRCA mutational status were analyzed.</p><p><strong>Results: </strong>Positive p16 stromal expression was found in 6 out of 38 (15,78%) patients with wild-type BRCA and in only 1 of the 22 (4,50%) patients with mutated BRCA. Conversely, positive α-SMA expression was detected in 34 of 38 patients with wild-type BRCA (89,47%) and in 21 of 22 patients (95,45%) with mutated BRCA. There was a significant difference (r = -0,32) between the negative stromal p16 expression and the positive stromal expression of α-SMA.</p><p><strong>Conclusion: </strong>This study suggests a new correlation between stromal expression of p16 and α-SMA and BRCA mutational status in EOC. Further investigations are strongly warranted to improve the understanding of the landscape of this malignancy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"79"},"PeriodicalIF":2.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Nomograms based on ratio indexes to predict severity and prognosis in immune checkpoint inhibitors-related myocarditis: a retrospective analysis.","authors":"Zhenli Li, Tiezhu Yao, Guang Liu, Zhengkun Guan, Jing Liu, Ling Guo, Jingtao Ma","doi":"10.1007/s00432-025-06110-3","DOIUrl":"10.1007/s00432-025-06110-3","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"74"},"PeriodicalIF":2.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis.","authors":"Shi-Jia Liu, Xiao Zhang, Lun-Jie Yan, Han-Chao Wang, Zi-Niu Ding, Hui Liu, Guo-Qiang Pan, Cheng-Long Han, Bao-Wen Tian, Zhao-Ru Dong, Dong-Xu Wang, Yu-Chuan Yan, Tao Li","doi":"10.1007/s00432-025-06082-4","DOIUrl":"10.1007/s00432-025-06082-4","url":null,"abstract":"<p><p>There are several meta-analyses about the comparison of tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) for preventing hepatocellular carcinoma in patients with chronic HBV infection published in recent years. However, the conclusions vary considerably. This umbrella review aims to consolidate evidence from various systematic reviews to evaluate differences in hepatocellular carcinoma prevention between two drugs. Systematic searches were conducted using PubMed, Embase, and Web of Science to identify original meta-analyses. Finally, twelve studies were included for quantitative analyses. We found that TDF treatment was associated with a significantly lower risk of HCC than ETV (hazard ratio, 0.80; 95% CI 0.75-0.86, p < 0.05). The lower risk of HCC in patients given TDF compared with ETV persisted in subgroup analyses performed with propensity score-matched cohorts, cirrhosis cohorts, nucleos(t)ide naïve cohorts and Asian cohorts. In the cohorts of non-Asia and patients without cirrhosis, there was no difference exhibited between these two drugs. Subsequent analyses showed TDF treatment was also associated with a lower incidence of death or transplantation than patients receiving ETV. Overall, the preventive effect of these two drugs on HCC has been studied in several published meta-analyses, but few were graded as high-quality evidence, meanwhile, most of which had high overlap. Thus, future researchers should include updated cohorts or conduct prospective RCTs to further explore this issue.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"77"},"PeriodicalIF":2.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does distance to the hospital affect the course of treatment and follow-up for children with Acute Lymphoblastic Leukemia?","authors":"Cecilie Bjerregaard Brix, Mette Bitsch Linck Hansen, Rikke Io Jessen, Cecilie Møller Høymark, Regitze Gyldenholm Skals, Søren Hagstrøm, Ninna Brix","doi":"10.1007/s00432-025-06127-8","DOIUrl":"10.1007/s00432-025-06127-8","url":null,"abstract":"<p><strong>Purpose: </strong>Centralization of specialized healthcare including treatment of children with acute lymphoblastic leukemia (ALL) has increased in high-income countries. We aimed to clarify whether the distance to the hospital for children with ALL affects the course of treatment regarding the number and duration of hospitalizations, outpatient clinic visits, missed appointments in the outpatient clinic, the duration of follow-up, or survival.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of children diagnosed with ALL aged 0-14 at Aalborg University Hospital from 1996 to 2018. Data was collected through registries and medical records. Comparisons of cancer- and sociodemographic characteristics in children with long versus short distance were made, divided at 42 km. Outcome variables were assessed by correlation and regression analyses. We compared overall survival using Kaplan-Meier.</p><p><strong>Results: </strong>The cohort consisted of 95 children. Cancer- and sociodemographic characteristics of the children with long versus short distance were similar, though the children with long distance were older and had less infections during treatment. There was no significant difference between the two groups regarding the number of hospitalizations, outpatient clinic visits, missed appointments, the duration of follow-up, or survival. Though, the summarized length of hospitalization was shorter for the group with long distance, when adjusting for age (-23 days (95% CI -45;-1)).</p><p><strong>Conclusion: </strong>No significant differences between the course of treatment and follow-up for children with long and short distance to the hospital was revealed, except for a shorter summarized length of hospitalization for children with long distance.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"76"},"PeriodicalIF":2.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global evolution of breast cancer incidence in childbearing-age women aged 15-49 years: a 30-year analysis.","authors":"Chengwei Xia, Yini Liu, Wei Yong, Xin Qing","doi":"10.1007/s00432-025-06113-0","DOIUrl":"10.1007/s00432-025-06113-0","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) poses an increasing threat to women's health, yet its characteristics in women of childbearing age (WCBA) are infrequently reported. This study aims to investigate the patterns and trends in BC incidence among WCBA over the past decades.</p><p><strong>Materials and methods: </strong>This study focuses on BC incidence in women aged 15-49 years, consistent with the WHO definition of WCBA. Estimates and 95% uncertainty intervals (UIs) for BC incidence in WCBA were obtained from the Global Burden of Diseases Study 2021. We utilized an age-period-cohort (APC) model to estimate the overall annual percentage change in incidence (net drift, % per year) and the annual percentage change within each age group (local drift, % per year). This model also provided fitted longitudinal age-specific rates adjusted for period deviations (age effects) and period/cohort relative risks (period/cohort effects) from 1992 to 2021.</p><p><strong>Results: </strong>In 2021, the global incidence of BC among WCBA was 561.44 thousand (95% UI 519.76 to 606.99). Between 1992 and 2021, the estimated annual change in BC incidence among WCBA was 0.47 (95% CI 0.41-0.52) worldwide, ranging from -0.43 (95% CI -0.54--0.31) in High sociodemographic index (SDI) region to 2.03 (95% CI 1.97-2.1) in Low-middle SDI region. Local drift analysis showed that higher SDI regions had higher age-standardized incidence rates among WCBA, with age effects demonstrating similar patterns across different SDI regions and increasing risk with age. Notably, the rising trend in BC incidence among WCBA occurs at progressively younger ages. Globally, unfavorable period and cohort effects were observed. All SDI regions exhibited increased period and cohort risks, except for the High SDI region, which saw a reduction in incidence rates influenced by period and cohort effects, particularly among those born after 1996.</p><p><strong>Conclusion: </strong>The increasing incidence of BC among WCBA highlights the urgent need for effective intervention and preventive policies to alleviate this growing global burden.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"75"},"PeriodicalIF":2.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}